In Q4 2017, ISR surveyed 177 professionals from biopharmaceutical sponsors to ask about their companies’ current stances on selling and on manufacturing biosimilars. By looking at the differences in stances on selling versus manufacturing biosimilars, the data show there is some opportunity for CMOs to secure biosimilar manufacturing projects. To learn more, follow the link to the Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition) report preview.   Originally published at Bioprocess Online.   View File